Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poggi, A.
Right arrow Articles by Zocchi, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poggi, A.
Right arrow Articles by Zocchi, M. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 13, 7205-7209, March 27, 1998

Involvement of Dihydropyridine-sensitive Calcium Channels in Human Dendritic Cell Function
COMPETITION BY HIV-1 TAT*

Alessandro PoggiDagger , Anna Rubartelli§, and M. Raffaella Zocchi§par

From the Dagger  Laboratory of Immunopathology, National Institute for Cancer Research and Advanced Biotechnology Center and the § Laboratory of Clinical Pathology, National Institute for Cancer Research, Genoa 16132, Italy and the  Laboratory of Tumor Immunology, Scientific Institute San Raffaele, Milan 20132, Italy

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The entry of extracellular calcium in leukocytes mediates several cellular processes; however, unlike in excitable tissues, the underlying molecular mechanisms are poorly defined. In this paper we provide phenotypical and biochemical evidence that peripheral blood-derived human dendritic cells express dihydropyridine-sensitive calcium channels. Exposure to the dihydropyridine drug nifedipine, which binds L-type calcium channels blocking calcium influx, prevents two dendritic cell functions that are dependent on extracellular calcium entry: apoptotic body engulfment and interleukin-12 production induced by cross-linking of the surface lectin NKRP1A. It is known that exogenous human immunodeficiency virus, type 1 Tat affects several Ca2+-dependent immune cell responses. Here we demonstrate that Tat inhibits apoptotic body engulfment and interleukin-12 production by blocking extracellular calcium influx. This inhibition is prevented by the calcium channel agonist dihydropyridine derivative Bay K 8644, suggesting the involvement of L-type calcium channels. This hypothesis is further supported by the observation that Tat and dihydropyridine drugs compete for binding to dendritic cells. Taken together, these findings indicate that exogenous Tat exerts its inhibitory effects on dendritic cells by blocking dihydropyridine-sensitive L-type calcium channels.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Calcium-linked cellular functions in excitable tissues are mediated by voltage-dependent calcium channels, which participate in the regulation of action potential generation, muscle contraction, and secretion of hormones or neurotransmitters (1). Although in neurons multiple types of calcium channels, which can be distinguished by their pharmacological properties, are expressed, in skeletal and cardiac muscles the principal calcium channels are L-type (1, 2). These channels are composed of three transmembrane subunits (alpha 1C, gamma , and the alpha 2delta complex) and one cytoplasmic chain (the beta 1 chain). A spectrum of compounds, the dihydropyridine (DHP)1 derivatives, which specifically bind with high affinity to the alpha 1C chain of L-type channels (3, 4), regulating their functional state from blocking to opening, allows both the identification and the functional analysis of this class of molecules (1-4).

Cytosolic calcium rise is an important signal also in nonexcitable cells, including immune cells, regulating fundamental processes such as activation, growth, and differentiation (5-7). Increase in free intracellular calcium concentration ([Ca2+]i) may result from calcium mobilization from either intracellular stores or extracellular medium or both (5). Unlike the mechanisms mediating mobilization from intracellular stores, the molecular structures mediating extracellular calcium influxes are still poorly characterized. Recently, the presence of functional calcium channels displaying DHP sensitivity has been observed in B lymphocytes (8), raising the possibility that similar structures are present also in nonexcitable cells. We have previously shown that some functions of dendritic cells (DC) are mediated by [Ca2+]i increase. DC are professional antigen presenting cells able to endocytose and process soluble or particulated antigens (9, 10) and prime naive T lymphocytes (9). Activated DC produce IL-12, a cytokine that amplifies the immune response promoting the differentiation of the T helper 1 lymphocyte subset, which in turn substains the natural killer (NK) cell activity (11, 12). We reported that activation of DC by cross-linking of the surface lectin NKRP1A with consequent IL-12 production is accompanied by extracellular calcium influx (13); similarly, apoptotic body engulfment induces and is dependent on calcium entry in phagocytosing DC (10). Interestingly, the HIV-1 transactivating factor Tat, which can be released by infected cells and play a number of extracellular roles (14), affects several calcium-mediated events in immune cells (15-18), including the phagocytosis of apoptotic cells by DC (19). We thus investigated the presence of calcium channels on DC and the possible interference by exogenous Tat. Our data indicate that functional DHP-sensitive L-type calcium channels are expressed by DC and regulate both apoptotic body engulfment and NKRP1A-mediated IL-12 production. Interestingly, L-type calcium channels appear to be the molecular target of HIV-1 Tat on DC; indeed, binding of DHP derivatives to these channels is cross-inhibited by Tat. Moreover, the inhibitory effect of HIV-1 Tat on DC function is antagonized by the DHP agonist Bay K 8644 (2).

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Reagents-- The acetoxymethyl ester of FURA 2 (FURA 2-AM) and all the reagents for electrophoresis were from Sigma. Prestained molecular weight markers were from Bio-Rad.

Ionomycin, nifedipine (NFP), and (±) Bay K 8644 (the net functional effect of the racemic mixture is that of the negative enantiomer, which is a L-type Ca2+ channel agonist) were from Calbiochem-Inalco S.p.A (Milan, Italy). Fluorescein DM-BODIPY® DHP was from Molecular Probes Europe (Leiden, the Netherlands). Chemically synthesized and biotinylated HIV-1 Tat protein were provided by Tecnogen (Piana di Monteverna, Cesena, Italy). Synthetic Tat preparations were purified by reverse phase high pressure liquid chromatography yielding a purity of 96%. The biological activities of synthetic Tat were superimposable to those of natural Tat in different assays (20, 21). Recombinant fibronectin type III repeat (Fn-III, from amino acids 1086-1172) was a kind gift of L. Zardi (National Institute for Cancer Research, Genoa, Italy). RPMI 1640, fetal calf serum, L-glutamine, and penicillin-streptomycin were from Biochrom (Berlin, Germany). Recombinant granulocyte-macrophage colony-stimulating factor was from Schering-Plow (Milan, Italy).

Engulfment of Apoptotic Bodies by Dendritic Cells-- Peripheral blood monocytes were isolated from healthy donors as described (10, 22) and cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, 10% heat-inactivated fetal calf serum, and 20 ng/ml granulocyte-macrophage colony-stimulating factor for 10 days to obtain monocyte-derived DC. Media were shown to be endotoxin-free using the Limulus lysate colorimetric assay (Procedures and Biological Information International, Milan, Italy). The human Jurkat T cell line (clone JA3) was purchased from the American Type Culture Collection (ATCC, Rockville, MD).

Apoptosis was induced by sublethal irradiation of JA3 cells (4000 radiation absorbed doses) and culture at 37 °C for 20 h. Engulfment assay was performed as described previously (10, 19, 23). Briefly, apoptotic bodies were labeled with 51Cr (sodium chromate, NEN-DuPont Italiana S.p.A., Cologno Monzese, MI, Italy, 50 µCi/106 cells) for 1 h at 37 °C, washed, and coincubated with adherent DC (2:1 ratio) at 37 °C (4 °C for the negative control). After 45 min, noningested apoptotic bodies were removed by four gentle washings and DC-associated radioactivity measured in a gamma -counter (Beckman Instruments Inc., Irvine, CA) after cell lysis. Results are expressed as a percentage of engulfment calculated as described (10, 19, 23). In some experiments DC were pretreated for 20 min with different concentrations of Tat (from 100 to 1 nM) or with Tat 100 nM plus Bay K 8644 10 µM; in other experiments, Bay K 8644 10 µM was added immediately prior apoptotic body challenge to untreated or Tat-pretreated cells. Drug concentrations were chosen on the basis of titration experiments (not shown).

Single Cell Analysis of Calcium Fluxes by Video Microscopy and Ratio Imaging-- Single cell analysis of calcium fluxes was performed as described (10, 19). Briefly, DC cultured on round coverslips were loaded with 1 µM FURA 2-AM (1 h at 37 °C), placed in a micro-incubator (Medical System Corp., Greenvale, NY) on an inverted epi-fluorescence Axiovert 10 microscope (Zeiss, Oberkochen, Germany), and maintained at 37 °C by a temperature controller (TC-202, Medical System). FURA 2 was excited with a high pressure 75 W xenon arc lamp fitted with appropriate filters on a shutter controlled by a Pentium 90 MHz computer. Excitation light was at 334 and 380 nm; emitted light was filtered at 510 nm. Two 334/380 ratio were taken each second, and video images were collected with an intensified charged coupled device (CCD) camera (ATTO Instruments, INC., Rockville, MD) and recorded every 15 s using the image processor program Attofluor RatioVision 6.08 (ATTO Instruments). Results were stored as a ratio of FURA 2 fluorescence at 334 nm divided by the fluorescence at 380 nm excitation. [Ca2+]i was calculated according to Grynkiewicz et al. (24). [Ca2+]i increases were measured upon apoptotic body interaction with DC or after DC treatment with either Bay K 8644 (10 µM) or ionomycin (1 µM). Alternatively, [Ca2+]i was measured after cross-linking of the NKRP1A molecule, obtained by incubation of DC with 5 µg/ml of the specific F(ab')2 mAb (20 min at 4 °C) followed by 10 µg/ml of F(ab')2 GAM added during the test at 37 °C as described (13). Cross-linking of CD31 or exposure of DC to GAM F(ab')2 alone did not elicit [Ca2+]i increases (13). In some experiments, DC were pretreated with NFP (1 or 10 µM) or HIV-1 Tat (from 100 to 10 nM) for 20 min, before challenge with apoptotic bodies, Bay K 8644, ionomycin, or NKRP1A cross-linking.

Calcium Channel Detection by Fluorescence-- DC (106/sample), untreated or preincubated 20 min with HIV-1 Tat or with Bay K 8644 or with Fn-III as a control (from 0.1 to 1 µM), were stained with 3 nM DM-BODIPYR DHP (4) and run on a FACSort (Becton Dickinson, Mountain View, CA). The concentrations of calcium channel antagonists reported to cross-inhibit the binding of 3 nM DM-BODIPYR DHP or other DHP derivatives range 10-500-fold (4). Alternatively, DC untreated or pretreated for 20 min with HIV-1 Tat or with BayK 8644 or with Fn-III (from 1 to 10 µM) were stained with biotinylated HIV-1 Tat (20) followed by phycoerythrin-streptavidin and analyzed by FACSort. Results are expressed as mean of fluorescence intensity (MFI).

Cytokine Production-- DC (2 × 106/sample), cultured in 1% Nutridoma (Boehringer Mannheim Italia, Monza, MI, Italy) untreated or treated for 20 min with NFP 10 µM or with different concentrations of Tat (from 100 to 1 nM) or with Tat 100 nM plus Bay K 8644 10 µM or with Bay K 8644 10 µM alone were challenged by cross-linking of the NKRP1A molecule with the F(ab')2 of a specific monoclonal antibody followed by GAM F(ab')2, as described (13). Cross-linking of CD31 or exposure of DC to GAM F(ab')2 alone did not stimulate IL-12 production (13). Supernatants were collected after 3 h, and secreted IL-12 was measured using the enzyme-linked immunosorbent assay kit for human IL-12 (p40 and p70) purchased from Endogen (Woburn, MA).

Western Blot-- After separation by SDS-polyacrylamide gel electrophoresis (12%) under reducing conditions, lysates from DC (50 µg of protein/sample; protein dosage performed with the Detergent-Compatible Bio-Rad kit based on the colorimetric Lowry method, Bio-Rad) or A431 cells (positive control, Transduction Laboratories, Lexington, KY) were electrotransferred onto nitrocellulose filters (Hybond ECL, Amersham Italia S.r.l., Milan, Italy) as described (13). Filters were blocked overnight with 10% nonfat dry milk in phosphate-buffered saline and then incubated 1 h with the anti-calcium channel beta 1 subunit mAb (clone 44, Transduction Laboratories), at 1:250 dilution, followed by horseradish peroxidase-conjugated GAM Ig (DAKO S.p.A., Milan, Italy, 1:10,000 dilution). The immunoreactive bands were revealed by luminol reaction (ECL, Amersham).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The DHP Drug NFP Prevents Calcium Mobilization and Engulfment of Apoptotic Bodies by Dendritic Cells-- We have previously shown that apoptotic body engulfment by DC elicits [Ca2+]i rises, mainly due to the entry of extracellular calcium, that are essential for phagocytosis (10, 19). The possibility of an involvement of calcium channels in this process has been investigated by using the inhibitory DHP derivative NFP, which specifically binds to the alpha 1C subunit of L-type calcium channels (1-4). As shown in Fig. 1A, NFP inhibits in a dose-dependent manner the calcium mobilization that follows the interaction between apoptotic bodies and DC. Likewise, engulfment is prevented by DC exposure to this drug (Fig. 1B). These results suggest that DC express functional L-type calcium channels. This was confirmed by the finding of a specific 58-kDa band detectable by Western blot analysis of DC lysates with a monoclonal antibody recognizing the beta 1 calcium channel subunit (Fig. 1C). Unlike in excitable tissues, these channels are voltage-independent, because exposure of DC to 50 mM KCl failed to induce a calcium influx (not shown).


View larger version (34K):
[in this window]
[in a new window]
  		Fig. 1.   DHP-sensitive calcium channels participate in apoptotic body engulfment by DC. A, DC cultured on round coverslips and loaded with 1 µM FURA 2-AM were challenged at 37 °C with apoptotic bodies (AB) at a ratio of 1:2. [Ca2+]i was monitored with an inverted epi-fluorescence microscope connected to an intensified CCD camera. Results are expressed as [Ca2+]i nM. Calcium fluxes were measured during interaction between DC and apoptotic bodies as such or after pretreatment with NFP (10 or 1 µM). One representative experiment out of six is shown. B, apoptotic bodies labeled with 51Cr were co-incubated with adherent DC (2:1 ratio) at 37 °C in the absence or presence of NFP (10 or 1 µM). Noningested AB were removed by washing and DC-associated radioactivity measured in a gamma -counter after cell lysis. Results are expressed as percentages of engulfment calculated as described (10, 19). C, after separation by SDS-polyacrylamide gel electrophoresis (12% gel) under reducing conditions, lysates from DC (50 µg) or A431 cells (positive control) were electrotransferred onto nitrocellulose filters, hybridized with anti-calcium channel beta 1 subunit mAb followed by horseradish peroxidase-GAM Ig, and developed by chemiluminescence.

HIV-1 Tat Prevents the Opening of DHP-sensitive Calcium Channels and Competes with DHP Derivatives for Binding to DC-- Exogenous HIV-1 Tat is able to inhibit both apoptotic body engulfment by DC and the [Ca2+]i rise induced by apoptotic body-DC interaction (19). We thus investigated whether the inhibitory effect of Tat is due to the block of L-type calcium channels on DC. DC were loaded with apoptotic bodies, and the engulfment was measured under different conditions. Fig. 2A shows that the inhibition of engulfment observed in the presence of HIV-1 Tat is prevented by DC pretreatment with Bay K 8644, a calcium channel agonist that induces Ca2+ entry by opening L-type channels (2, 8). In turn, once DC have been pretreated with Tat, Bay K 8644 is unable to revert the inhibition (Fig. 2A). The calcium influx elicited in DC by exposure to Bay K 8644 is blocked by pretreatment of DC with HIV-1 Tat in a dose-dependent manner (Fig. 2B); in contrast, Tat does not affect the calcium channel-independent calcium rise that follows DC exposure to the ionophore ionomycin (Fig. 2C). These data suggest that HIV-1 Tat competes with Bay K 8644 for binding to DHP-sensitive calcium channels. To further confirm this hypothesis, we performed fluorescence-activated cell sorter analysis of DC stained with DM-BODIPYR DHP, a fluorescent DHP derivative that binds to the alpha 1C chain of L-type calcium channels (4), in the presence or absence of Tat or Bay K 8644. As shown in Fig. 3A, DM-BODIPYR DHP stains DC, indicating the presence of L-type channel alpha 1C subunit on these cells. Tat antagonizes the DM-BODIPYR DHP binding with the same dose response as the alpha 1C ligand Bay K 8644. In turn, the binding of biotinylated Tat to DC is cross-inhibited by pretreatment of the cells with Bay K 8644 (Fig. 3B). In both cases, the unrelated peptide Fn-III, displaying the same length as HIV-1 Tat, has no effects (Fig. 3, A and B).


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 2.   HIV-1 Tat interferes with calcium channel functions in DC. A, adherent DC were untreated (open column, Nil) or pretreated 20 min with Tat from 100 to 1 nM (closed column) or with Tat 100 nM plus Bay K 8644 10 µM (hatched column). In some experiments, Bay K 8644 10 µM was added immediately prior apoptotic body challenge to untreated (light gray column) or Tat-pretreated cells (dark gray column). Engulfment was performed as described for Fig. 1. Results are expressed as percentages of engulfment calculated as described (10, 19). B and C, DC cultured on round coverslips and loaded with 1 µM FURA 2-AM untreated or pretreated with Tat from 100 to 1 nM (B) or Tat 100 nM (C) were challenged with Bay K 8644 10 µM (B) or ionomycin 1 µM (C). [Ca2+]i was monitored with an inverted epi-fluorescence microscope connected to an intensified CCD camera. Results are expressed as [Ca2+]i nM. One representative experiment out of six is shown.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 3.   Bay K 8644 and HIV-1 Tat compete for binding to DC. A, DC untreated or pretreated for 20 min with Tat or Bay K 8644 or Fn-III peptide at different concentrations, as indicated, were stained with 3 nM DM-BODIPYR DHP and analyzed by FACSort (Becton Dickinson). Results are expressed as MFI (arbitrary units). B, DC untreated or pretreated for 20 min with Tat or Bay K 8644 or Fn-III peptide at different concentrations, as indicated, were stained with biotinylated Tat (Tat-biot) followed by phycoerythrin-streptavidin (PE-Av) and analyzed by FACSort. Results are expressed as MFI (arbitrary units).

Both HIV-1 Tat and the DHP Drug NFP Inhibit IL-12 Secretion by DC-- An important function of DC is to support T helper cell differentiation by IL-12 production (11, 12). Secretion of IL-12 is induced by various stimuli (11, 12); one of them is cross-linking of the surface lectin NKRP1A (13). Because this triggering also results in Ca2+ entry (13), we investigated whether L-type calcium channels play a role in IL-12 release. NKRP1A molecules were cross-linked by the specific monoclonal antibody, and the secretion of IL-12 by DC in the presence or absence of NFP or HIV-1 Tat was measured. Fig. 4A shows that the engagement of NKRP1A results in release of IL-12, which is prevented by exposure of DC to NFP. HIV-1 Tat proves to exert the same inhibition of NFP on NKRP1A-induced IL-12 production (Fig. 4A). This inhibition was dose-dependent, being detectable up to 10 nM Tat (Fig. 4A). Again, the calcium channel agonist Bay K 8644 is able to revert the inhibitory effect of HIV-1 Tat (Fig. 4A). In keeping with these results, the calcium rise elicited by NKRP1A cross-linking in DC is inhibited by either the DHP drug NFP (Fig. 4B) or HIV-1 Tat (Fig. 4C), further supporting the hypothesis that both compounds exert their effects by acting on L-type calcium channels.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 4.   NKRP1A-induced Ca2+ influx and IL-12 secretion are inhibited by NFP and HIV-1 Tat. A, DC (105/sample) were challenged by cross-linking of the NKRP1A molecule after the following treatments: no treatment (Nil, hatched column), NFP 10 µM (dotted column), 10-100 nM Tat (closed columns), Bay K 8644 10 µM followed by Tat 100 nM (dark gray column), or Bay K 8644 10 µM alone (light gray column). IL-12 was measured in the supernatants by enzyme-linked immunosorbent assay after 3 h. The open column (Nil) represents supernatants from noncross-linked DC. B and C, DC cultured on round coverslips and loaded with 1 µM FURA 2-AM, untreated or pretreated with NFP (B, 1 or 10 µM) or Tat (C, 10-100 nM) were challenged by cross-linking of the NKRP1A molecule. [Ca2+]i was monitored with an inverted epi-fluorescence microscope connected to an intensified CCD camera. Results are expressed as [Ca2+]i nM. One representative experiment out of six is shown.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In the present paper we show that molecular structures displaying pharmacological properties of L-type calcium channels (1, 2) mediate extracellular calcium influx in human DC. The presence of functional L-type Ca2+ channels in DC is supported by three lines of evidence: (i) Ca2+-dependent DC functions, such as apoptotic body engulfment and IL-12 production, are inhibited by L-type Ca2+ channel blockers; (ii) fluorescent DHP drugs, specific for the alpha 1C chain of L-type channels (3, 4), bind to DC surface; and (iii) the calcium channel beta 1 chain is detectable in DC lysates. In contrast, N-type calcium channels (1, 25) are not expressed, because fluorescent omega -conotoxin failed to stain DC (not shown). Although L-type calcium channels in excitable tissues are voltage-gated (1), DHP-sensitive Ca2+ channels in DC are voltage-independent, suggesting that they lack a membrane voltage sensor. This finding supports the recently reported data on the existence of voltage-independent DHP-sensitive channels on B lymphocytes (8), raising the possibility of a common mechanism responsible for Ca2+ entry in immune cells.

An important novel finding of this paper is that HIV-1 Tat blocks two calcium-mediated DC functions by acting on DHP-sensitive Ca2+ channels. Indeed, Tat-mediated inhibition of both apoptotic body engulfment and NKRP1A-induced IL-12 production is reverted by the L-type Ca2+-channel agonist Bay K 8644. In turn, Tat blocks the Ca2+ influx that follows triggering of DC with Bay K 8644. The finding that DHP derivatives and Tat compete for binding to DC strongly supports the hypothesis that L-type calcium channels are the molecular targets of the inhibitory effects of Tat on DC. Several Tat binding molecules have been described on different cell types; Tat binds with high affinity vascular endothelial growth factor receptor (21) and CD26 (26), with low affinity heparan sulfates (27), and with integrins like alpha vbeta 3 (28) or alpha 5beta 1 (29). DHP drugs are able to strongly decrease the binding of biotinylated Tat to DC; thus, one major binding site for Tat on these cells seems to be represented by DHP-sensitive channels, although we cannot rule out binding to other receptors, which in turn can be associated to Ca2+ channels.

The role of HIV-1 Tat in AIDS pathogenesis extends beyond its transcriptional activity; indeed, it is secreted by infected cells (14) and affects gene expression and function in many types of infected or noninfected cells (17, 18, 30-32). Exogenous Tat proved to down-regulate immune cell functions; it inhibits antigen-induced T cell proliferation (15), blocks the phagocytosis of apoptotic cells (19), and modulates cytokine production (16, 31, 32). Here we show that exogenous Tat inhibits IL-12 production elicited by NKRP1A engagement in DC. IL-12, originally described as NK cell stimulatory factor, is also involved in the differentiation of T helper cell subset 1 cells (11, 12). A deficient IL-12 production in AIDS patients may thus play a role in the progression of the disease (33, 34), which is associated with decreased NK cell function, loss of T helper cell subset 1 cells, and a corresponding increase in T helper cell subset 2 cells (33, 35). In light of these considerations, our data provide evidence for a molecular mechanism possibly underlying T helper cell subsets 1 and 2 embalance during HIV-1 infection, based on the Tat-mediated impairment of IL-12 production. The physiological relevance of our findings relies on the observation that nanomolar concentrations of HIV-1 Tat are detectable in the sera of AIDS patients (36). It is conceivable that the local amount of Tat in the mucosal and lymphoid tissues site of infection is higher due to the concentrating effect of extracellular matrix components, such as heparan sulfates, which bind to Tat (27). This may explain the finding that in vitro, in the absence of matrix components, Tat is usually active at concentrations higher than those found in AIDS patient sera (15, 17, 29, 31, 32). Finally, the finding that Tat can act through blocking calcium channels may provide a universal key for understanding the molecular basis of exogenous Tat-mediated immunosuppressive effects during HIV-1 infection.

    ACKNOWLEDGEMENTS

We thank C. E. Grossi, L. Moretta, and C. Rugarli for support and L. Zardi for the gift of recombinant fibronectin peptide. We are also grateful to R. Sitia for criticisms and suggestions.

    FOOTNOTES

* This work was supported in part by grants from Associazione Italiana Ricerca sul Cancro, Ministero Sanità (Special Project AIDS 1996), and National Council for Research (Special Project Biotech).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

par To whom correspondence should be addressed: Laboratory of Clinical Pathology, Istituto Nazionale Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132 Genoa, Italy. Tel.: 39-10-5600204; Fax: 39-10-5600210; E-mail: annarub{at}hp380.ist.unige.it.

1 The abbreviations used are: DHP, dihydropyridines; CCD, charged coupled device; DC, dendritic cell(s); GAM, goat anti-mouse; Fn-III, fibronectin type III repeat; mAb, monoclonal antibody; MFI, mean fluorescence intensity; NFP, nifedipine; NK, natural killer; IL, interleukin; HIV, human immunodeficiency virus; FURA 2-AM, acetoxymethyl ester of FURA 2.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Catterall, W. A. (1995) Annu. Rev. Biochem. 64, 493-531[CrossRef][Medline] [Order article via Infotrieve]
  2. Glossmann, H., and Ferry, D. R. (1995) Methods Enzymol. 109, 513-550
  3. Catterall, W. A., and Striessnig, J. (1992) Trends Pharmacol. Sci. 13, 256-262[CrossRef][Medline] [Order article via Infotrieve]
  4. Berger, W., Prinz, H., Striessnig, J., Kang, H.-C., Haugland, R., and Glossmann, H. (1994) Biochemistry 33, 11875-11883[CrossRef][Medline] [Order article via Infotrieve]
  5. Gardner, P. (1989) Cell 59, 15-20[CrossRef][Medline] [Order article via Infotrieve]
  6. Bijsterbosch, M. K., Meade, C. M., Turner, G. A., Klaus, G. G. (1985) Cell 41, 999-1006[CrossRef][Medline] [Order article via Infotrieve]
  7. Clapham, D. E. (1995) Cell 80, 259-268[CrossRef][Medline] [Order article via Infotrieve]
  8. Sadighi Akcha, A. A., Willmott, N. J., Brickley, K., Dolphin, A. C., Galione, A., Hunt, S. V. (1996) J. Biol. Chem. 271, 7297-7300[Abstract/Free Full Text]
  9. Cella, M., Sallusto, F., and Lanzavecchia, A. (1997) Curr. Opin. Immunol. 9, 10-17[CrossRef][Medline] [Order article via Infotrieve]
  10. Rubartelli, A., Poggi, A., and Zocchi, M. R. (1997) Eur. J. Immunol. 27, 1893-1900[Medline] [Order article via Infotrieve]
  11. Scott, P. (1993) Science 260, 496-497[Free Full Text]
  12. Lamont, A. G., and Adorini, L. (1996) Immunol. Today 17, 214-217[CrossRef][Medline] [Order article via Infotrieve]
  13. Poggi, A., Rubartelli, A., Moretta, L., and Zocchi, M. R. (1997) Eur. J. Immunol. 27, 2965-2970[Medline] [Order article via Infotrieve]
  14. Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C., Wong-Staal, F. (1990) Nature 345, 84-86[CrossRef][Medline] [Order article via Infotrieve]
  15. Viscidi, R. P., Mayur, H. K., Lederman, M., and Frankel, A. D. (1989) Science 246, 1606-1608[Abstract/Free Full Text]
  16. Westerndorp, M. O., Li-Weber, M., Frank, R. W., Krammer, P. H. (1994) J. Virol. 68, 4177-4185[Abstract/Free Full Text]
  17. Li, C. J., Friedman, D. J., Wang, C., Metelev, V., and Pardee, A. (1995) Science 268, 429-431[Abstract/Free Full Text]
  18. Zauli, G., Ghibellini, D., Milani, D., Mazzoni, M., Borgatti, P., La Placa, M., Capitani, S. (1993) Cancer Res. 53, 4481-4485[Abstract/Free Full Text]
  19. Zocchi, M. R., Poggi, A., and Rubartelli, A. (1997) AIDS 11, 1227-1235[CrossRef][Medline] [Order article via Infotrieve]
  20. Morgavi, P., Bonifaci, N., Pagani, M., Costigliolo, S., Sitia, R., and Rubartelli, A. (1997) J. Biol. Chem. 272, 11256-11260[Abstract/Free Full Text]
  21. Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Salio, M., Camussi, G., Rockl, W., and Bussolino, F. (1996) Nat. Med. 2, 1371-1375[CrossRef][Medline] [Order article via Infotrieve]
  22. Sallusto, F., and Lanzavecchia, A. (1996) J. Exp. Med. 179, 1109-1118[Abstract/Free Full Text]
  23. Luciani, M. F., and Chimini, G. (1996) EMBO J. 15, 226-235[Medline] [Order article via Infotrieve]
  24. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450[Abstract/Free Full Text]
  25. Hille, B. (1994) Trends Neurol. Sci. 17, 531-536 [CrossRef][Medline] [Order article via Infotrieve]
  26. Gutheil, W. G., Subramanyam, M., Flentke, G. R., Sanford, D. G., Munoz, E., Huber, B. T., Bachovchin, W. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6594-6598[Abstract/Free Full Text]
  27. Albini, A., Benelli, R, Presta, M., Rusnati, M., Ziche, M., Rubartelli, A., Paglialunga, G., Bussolino, F., and Noonan, D. (1996) Oncogene 12, 289-297[Medline] [Order article via Infotrieve]
  28. Brake, D. A., Debouck, C., and Biesecker, G. (1993) J. Cell Biol. 121, 461-468[Abstract/Free Full Text]
  29. Barillari, G, Gendelman, R., Gallo, R. C., Ensoli, B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7941-7945[Abstract/Free Full Text]
  30. Frankel, A. D., and Pabo, C. O. (1988) Cell 55, 1189-1193[CrossRef][Medline] [Order article via Infotrieve]
  31. Lotz, M., Clark-Lewis, I., and Ganu, V. (1994) J. Cell Biol. 124, 365-371[Abstract/Free Full Text]
  32. Chen, P., Mayne, M., Power, C., and Nath, A. (1997) J. Biol. Chem. 272, 22385-22388[Abstract/Free Full Text]
  33. Chehimi, J., Starr, S. E., Frank, I., D'Andrea, A., Ma, X., MacGregor, R. R., Sennelier, J., Trinchieri, G. (1994) J. Exp. Med. 179, 1361-1366[Abstract/Free Full Text]
  34. Clerici, M., Lucey, D. R., Berzofsky, J. A., Pinto, L. A., Wynn, T. A., Blatt, S. P., Dolan, M. J., Hendrix, C. W., Wolf, S. F., Shearer, G. M. (1993) Science 262, 1721-1724[Abstract/Free Full Text]
  35. Clerici, M., and Shearer, G. M. (1993) Immunol. Today 14, 107-111[CrossRef][Medline] [Order article via Infotrieve]
  36. Westerndorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K. M., Krammer, P. H. (1995) Nature 375, 497-500[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Vukcevic, G. C. Spagnoli, G. Iezzi, F. Zorzato, and S. Treves
Ryanodine Receptor Activation by Cav1.2 Is Involved in Dendritic Cell Major Histocompatibility Complex Class II Surface Expression
J. Biol. Chem., December 12, 2008; 283(50): 34913 - 34922.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Gomes, M. Savignac, M. D. Cabral, P. Paulet, M. Moreau, C. Leclerc, R. Feil, F. Hofmann, J.-C. Guery, G. Dietrich, et al.
The cGMP/Protein Kinase G Pathway Contributes to Dihydropyridine-sensitive Calcium Response and Cytokine Production in TH2 Lymphocytes
J. Biol. Chem., May 5, 2006; 281(18): 12421 - 12427.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Andrei, P. Margiocco, A. Poggi, L. V. Lotti, M. R. Torrisi, and A. Rubartelli
From The Cover: Phospholipases C and A2 control lysosome-mediated IL-1{beta} secretion: Implications for inflammatory processes
PNAS, June 29, 2004; 101(26): 9745 - 9750.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Savignac, B. Gomes, A. Gallard, S. Narbonnet, M. Moreau, C. Leclerc, P. Paulet, B. Mariame, P. Druet, A. Saoudi, et al.
Dihydropyridine Receptors Are Selective Markers of Th2 Cells and Can Be Targeted to Prevent Th2-Dependent Immunopathological Disorders
J. Immunol., May 1, 2004; 172(9): 5206 - 5212.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. L. Petersen, C. R. Morris, and J. C. Solheim
Virus Evasion of MHC Class I Molecule Presentation
J. Immunol., November 1, 2003; 171(9): 4473 - 4478.
[Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. Poggi, R. Carosio, A. Rubartelli, and M. R. Zocchi
{beta}3-Mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat
J. Leukoc. Biol., March 1, 2002; 71(3): 531 - 537.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. M. Spaggiari, P. Contini, R. Carosio, M. Arvigo, M. Ghio, D. Oddone, A. Dondero, M. R. Zocchi, F. Puppo, F. Indiveri, et al.
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily
Blood, March 1, 2002; 99(5): 1706 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Dellis, S. C. Gangloff, M. Paulais, D. Tondelier, J.-P. Rona, F. Brouillard, F. Bouteau, M. Guenounou, and J. Teulon
Inhibition of the Calcium Release-activated Calcium (CRAC) Current in Jurkat T Cells by the HIV-1 Envelope Protein gp160
J. Biol. Chem., February 15, 2002; 277(8): 6044 - 6050.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Poggi, R. Carosio, G. M. Spaggiari, C. Fortis, G. Tambussi, G. Dell'Antonio, E. Dal Cin, A. Rubartelli, and M. R. Zocchi
NK Cell Activation by Dendritic Cells Is Dependent on LFA-1-Mediated Induction of Calcium-Calmodulin Kinase II: Inhibition by HIV-1 Tat C-Terminal Domain
J. Immunol., January 1, 2002; 168(1): 95 - 101.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Gardella, C. Andrei, L. V. Lotti, A. Poggi, M. R. Torrisi, M. R. Zocchi, and A. Rubartelli
CD8+ T lymphocytes induce polarized exocytosis of secretory lysosomes by dendritic cells with release of interleukin-1{beta} and cathepsin D
Blood, October 1, 2001; 98(7): 2152 - 2159.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-f. Hsu, P. J. O'Connell, V. A. Klyachko, M. N. Badminton, A. W. Thomson, M. B. Jackson, D. E. Clapham, and G. P. Ahern
Fundamental Ca2+ Signaling Mechanisms in Mouse Dendritic Cells: CRAC Is the Major Ca2+ Entry Pathway
J. Immunol., May 15, 2001; 166(10): 6126 - 6133.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Badou, Y. Bennasser, M. Moreau, C. Leclerc, M. Benkirane, and E. Bahraoui
Tat Protein of Human Immunodeficiency Virus Type 1 Induces Interleukin-10 in Human Peripheral Blood Monocytes: Implication of Protein Kinase C-Dependent Pathway
J. Virol., November 15, 2000; 74(22): 10551 - 10562.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
E. A. Lefevre, R. Krzysiek, E. P. Loret, P. Galanaud, and Y. Richard
Cutting Edge: HIV-1 Tat Protein Differentially Modulates the B Cell Response of Naive, Memory, and Germinal Center B Cells
J. Immunol., August 1, 1999; 163(3): 1119 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Zegarra-Moran, A. Rasola, M. Rugolo, A. M. Porcelli, B. Rossi, and L. J. V. Galietta
HIV-1 Nef Expression Inhibits the Activity of a Ca2+-Dependent K+ Channel Involved in the Control of the Resting Potential in CEM Lymphocytes
J. Immunol., May 1, 1999; 162(9): 5359 - 5366.
[Abstract] [Full Text] [PDF]